title: Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
abstract: BACKGROUND
  Recent case reports suggested a link between oral bisphosphonate use and esophageal cancer. We therefore examined the association between these medications and the risk of esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE).
  
  
  METHODS
  This was a nested, matched case-control study. Cases with incident EAC at least 6 months following BE index date were matched by incidence density sampling to controls with BE without EAC. Patients with BE were found in the national Department of Veterans Affairs computerized databases, and each filled prescriptions for oral bisphosphonates between BE diagnosis and EAC diagnosis (or corresponding dates in controls). Incidence density ratios were calculated using conditional logistic regression models.
  
  
  RESULTS
  In a cohort of 11,823 patients with BE, we compared 116 cases and 696 controls. Most were men (97%). Most cases and controls had at least one filled proton pump inhibitor (PPI) prescription (95 vs. 94%, P = 0.5). Filled bisphosphonate prescriptions were very uncommon (1.7 vs. 1.9%) and were not associated with EAC; the incidence density ratio was 0.92 (95% CI, 0.21-4.15).
  
  
  CONCLUSIONS
  In patients with BE, oral bisphosphonates were not associated with an increased risk of EAC.
authors.affiliation: Gastroenterology, Baylor College of Medicine, Houston, TX, USA.
authors.forename: Dang M
authors.initials: DM
authors.lastname: Nguyen
authors.forename: Jim
authors.initials: J
authors.lastname: Schwartz
authors.forename: Peter
authors.initials: P
authors.lastname: Richardson
authors.forename: Hashem B
authors.initials: HB
authors.lastname: El-Serag
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology*; D000368:Aged; D001471:Barrett Esophagus / Q000453:epidemiology*; D016022:Case-Control Studies; D004164:Diphosphonates / Q000627:therapeutic use*; D004938:Esophageal Neoplasms / Q000453:epidemiology*; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
chemical_list: D004164:Diphosphonates
references.citation: N Engl J Med. 2009 Jan 1;360(1):89-90
references.pmid: 19118315
references.citation: Gastroenterol Clin North Am. 1991 Dec;20(4):791-816
references.pmid: 1787014
references.citation: Arch Intern Med. 2001 Jan 8;161(1):107-10
references.pmid: 11146706
references.citation: J Natl Cancer Inst. 2005 Jan 19;97(2):142-6
references.pmid: 15657344
references.citation: Dig Dis Sci. 2002 Aug;47(8):1665-78
references.pmid: 12184516
references.citation: World J Surg. 2003 Sep;27(9):999-1008; discussion 1006-8
references.pmid: 12917764
references.citation: Gastroenterology. 2005 Dec;129(6):1825-31
references.pmid: 16344051
references.citation: Aliment Pharmacol Ther. 2008 Jun;27(12):1293-9
references.pmid: 18363892
references.citation: Am J Gastroenterol. 2002 Jan;97(1):58-64
references.pmid: 11808969
references.citation: Am J Manag Care. 2009 Mar 16;15(3):e1-8
references.pmid: 19298095
references.citation: Gastroenterol Clin North Am. 1997 Sep;26(3):455-66
references.pmid: 9309397